Nuvation Bio Inc.

Nuvation Bio Inc. (NUVB) is a clinical-stage biopharmaceutical company concentrated on oncology drug development that reached public markets through a business combination with Panacea Acquisition Corp. II, a blank-check company sponsored by Panacea Capital Management and listed on the New York Stock Exchange under the ticker PANA. The SPAC completed its initial public offering in 2020 targeting the healthcare and life sciences sector. The Form 8-K filed February 9, 2021, accession number 0001193125-21-034624, is associated with activity surrounding that de-SPAC transaction. Nuvation Bio, founded by oncologist and drug developer David Hung, focuses on differentiated therapies for cancer patients with limited treatment options. Sign up at SpacDesk for the full filing history, deal timeline, and data on this transaction.